Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Five Warning Signs of a Problem Overachiever
- Is someone on your team working themselves — or others — into the ground? Here s how to nip it in the bud before a serious problem develops. ...
- Articles 2007-11-26
Additional Resources
- Research links homocysteine levels, erectile dysfunction
- SAN ANTONIO -- Men who have abnormally high levels of homocysteine--a marker already linked to increased risk of coronary artery disease--may be at increased risk of erectile dysfunction, Ralf Herwig, M.D., said at the annual meeting of the American Urological Association. "The more severe the erectile dysfunction gets, the...
- Research articles 2005-09-01
- New Erectile Dysfunction Treatment Patent Granted to VIVUS
- MOUNTAIN VIEW, Calif.--BW HealthWire--March 24, 1999--VIVUS, Inc. (Nasdaq:VVUS) has been issued patent No. 5,886,039 for the "Method and Composition for Treating Erectile Dysfunction" by the U.S. Patent Office. This patent provides VIVUS with broad patent protection for the commercialization of ALIBRAtm, VIVUS' second-generation transurethral treatment for male erectile dysfunction ED.
- Research articles 1999-03-24
- Statement to the Media: Lilly ICOS Pleased with European Patent Office's Decision to Affirm Revocation of Pfizer's Patent on Treatment of Erectile Dysfunction.
- BOTHELL, Washington and INDIANAPOLIS, Indiana, February 10 /PRNewswire/ -- Lilly ICOS LLC (NYSE: LLY and Nasdaq: ICOS), marketer of CialisR tadalafil, a PDE5 inhibitor indicated for the treatment of erectile dysfunction ED, is pleased with BOTHELL, Washington and INDIANAPOLIS, Indiana, February...
- Research articles 2005-02-10
- Addressing Female Sexual Dysfunction, Finally; The Body Shop is Earth Friendly; College Students Shun Computer Tech Classes, CNNfn
- KATHLEEN HAYS, CNNfn ANCHOR, THE FLIPSIDE: When it comes to sexual dysfunction among women, some would say there aren`t a lot of treatments out there, but that apparently is starting to change. Joining us with a look at what`s in the pipeline now is KATHLEEN...
- Research articles 2004-09-20
- FDA warns on erectile dysfunction drugs.
- The US Food and Drug Administration FDA has warned doctors that a handful of erectile dysfunction drugs, including GlaxoSmithKline's GSK Levitra, could cause vision loss. The regulator says incidents have been reported among patients taking Levit The US Food and Drug Administration FDA has warned doctors...
- Research articles 2005-07-15
- Our Online Survey; 72%: U.S. will curb ED drug ads.(Viewpoint)(erectile-dysfunction)(Brief Article)
- 72% of over 750 respondents believe that Rep. James Moran will be successful with his effort to ban erectile-dysfunction drug ads on TV during daytime and prime-time hours. The remaining 28% believe he won't be able to get a bill through Congress. 72% of...
- Research articles 2005-02-28
- Mystery of the orgasm: Genetic link seen in women's sexual dysfunction
- PARIS AFP — British scientists say they have established a link between genetics and a woman's ability to experience orgasm, striking a blow at those who pin the blame for female sexual dysfunction on social or cultural factors. Previous research has documented the widespread phenomenon of women who never...
- Research articles 2005-06-07
- Erectile dysfunction prevalent in Asia: Pfizer
- SINGAPORE AFP — An estimated 20 percent of Asian men suffer from erectile dysfunction, an executive from pharmaceutical firm Pfizer said Tuesday. "It is a prevalent issue," Jude Selvaraj, Pfizer's medical adviser in Singapore and Malaysia, told AFP at the launch of Pfizer's new diagnostic kit to help men...
- Research articles 2007-04-24
- Yale researchers create topical estrogen that alleviates sexual dysfunction in menopausal women and eliminates side effects of conventional estrogen.
- M2 PRESSWIRE-9 May 2001-YALE UNIVERSITY: Yale researchers create topical estrogen that alleviates sexual dysfunction in menopausal women and eliminates side effects of conventional estrogen C1994-2001 M2 COMMUNICATIONS LTD RDATE:09052001 New Haven, Conn. -- To alleviate vaginal dyspareunia or dryness,...
- Research articles 2001-05-09
- Palatin Technologies expands patent portfolio in the treatment of sexual dysfunction.
- Palatin Technologies, Inc. (Cranbury, NJ) said that the European Patent Office has allowed claims on a patent application entitled, "Compositions for Treatment of Sexual Dysfunction" (European Patent 01196184). The European patent application corresponds to Palatin's United States Patents 6,579,968 and 6,794,489 which cover the specific...
- Research articles 2004-11-01
- Novel impotence remedy; no shots, surgery or pumps; painless drug application leads to successful intercourse for 70% of men with long-standing erectile dysfunction
- ATLANTA--BUSINESS WIRE--June 13, 1995--An exciting new non-surgical option to remedy impotence, even in older men with erectile dysfunction of many years duration, was reported here today at the American Diabetes Association's 55th Annual Scientific Sessions."This is the first report of successful use of a transurethral drug delivery system yielding not...
- Research articles 1995-06-13
- NexMed Presents Clinical Data On Femprox for Treating Female Sexual Dysfunction; U.S. Phase I Results to be Presented at Leading Workshop on FSD
- ROBBINSVILLE, N.J.,--BUSINESS WIRE--Oct. 20, 1999-- NexMed, Inc. (OTC-BB:NEXM) announced today that it will present its U.S. Phase I clinical data on the Femprox topical treatment for female sexual dysfunction ("FSD"), at Boston University School of Medicine's New Perspectives in the Management of Female Sexual Dysfunction, in Boston, October 22-24,...
- Research articles 1999-10-20
- DRAXIS - FDA Clears Anipryl - selegiline hydrochloride - For Canine Cognitive Dysfunction Syndrome - New Indication to be Launched in January 1999
- MISSISSAUGA, Ontario--BUSINESS WIRE--Dec. 11, 1998--DRAXIS Health Inc.(NASDAQ:DRAXF) (TSE:DAX.) DRAXIS Health Inc. today announced that AniprylR, a veterinary prescription medication licensed to Pfizer Inc. (NYSE - PFE), has been cleared by the U.S. Food and Drug Administration ("FDA") for the control of clinical signs associated with canine Cognitive Dysfunction Syndrome CDS....
- Research articles 1998-12-11
- BioLife Remedies, Inc. Announces the Opening of Sales of Dia-X (former name Di-Agra) for the Remedy of Erectile Dysfunction from Diabetes
- BioLife Remedies, Inc. (PINK SHEETS: BLRS) is pleased to announce that DIA-XTM is NOW available for retail and wholesale at www.blfrproducts.com . DIA-XTM is an herbal product developed by the company for men with Erectile Dysfunction from Diabetes.
- Research articles 2007-05-29
- NexMed Files NDA for Proprietary Erectile Dysfunction Treatment
- EAST WINDSOR, N.J. -- NexMed, Inc. (Nasdaq: NEXM), a developer of innovative transdermal products based on its proprietary NexACT([R]) drug delivery technology, today announced that it filed the New Drug Application NDA for its topically applied alprostadil cream for the treatment of erectile dysfunction with the U.S. Food and Drug...
- Research articles 2007-09-24
- Wyeth and Progenics Pharmaceuticals Announce Worldwide Collaboration to Develop and Commercialize Methylnaltrexone; Methylnaltrexone in Late-Stage Clinical Development for Opioid-Induced Constipation and Post-Operative Bowel Dysfunction
- MADISON, N.J. & TARRYTOWN, N.Y. -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE) and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that they have entered into an exclusive, worldwide agreement for the joint development and commercialization of methylnaltrexone MNTX for the treatment of opioid-induced side effects, including constipation and post-operative...
- Research articles 2005-12-23
- BioSante Pharmaceuticals Announces FDA Clarity on Development of LibiGel® in the Treatment of Female Sexual Dysfunction
- LINCOLNSHIRE, Ill. -- BioSante Pharmaceuticals, Inc. (AMEX:BPA) announced today that it has received clarity from and is in agreement with the U.S. Food and Drug Administration FDA on key FDA requirements for the development and approval of LibiGel in the treatment of female sexual dysfunction FSD, specifically, hypoactive sexual desire...
- Research articles 2007-09-11
- NexMed Confirms FDA Acceptance of NDA for Erectle Dysfunction Product
- EAST WINDSOR, N.J. -- NexMed, Inc. (Nasdaq: NEXM), a developer of innovative transdermal products based on its proprietary NexACT[R] drug delivery technology, today announced that the New Drug Application NDA filed by the Company for its erectile dysfunction ED product, a topically applied alprostadil cream, was accepted for review by...
- Research articles 2007-11-20
- PATIENTS PREFER ORAL ERECTILE DYSFUNCTION TREATMENT: STUDY.
- (Full text of a statement, contact details below) COLOGNE, Nov. 17 /PRNewswire-AsiaNet/ - Results of a new clinical study indicate that most men with erectile dysfunction ED prefer the new PDE5-inhibitor drugs to sildenafil Viagra and of these, nearly one-half of men prefer vardenafil Levitra(1), the product most...
- Research articles 2003-11-17
- << Previous
- page 1 of 1
- Next >>
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
